Common name
o-xylene
IUPAC name
o-xylene
SMILES
c1c(c(ccc1)C)C
Common name
o-xylene
IUPAC name
o-xylene
SMILES
c1c(c(ccc1)C)C
INCHI
InChI=1S/C8H10/c1-7-5-3-4-6-8(7)2/h3-6H,1-2H3
FORMULA
C8H10
Common name
o-xylene
IUPAC name
o-xylene
Molecular weight
106.165
clogP
2.831
clogS
-2.497
Frequency
0.0034
HBond Acceptor
0
HBond Donor
0
Total PolarSurface Area
0
Number of Rings
1
Rotatable Bond
0
| Drug ID | Common name | Structure CAS | Compound class | Therapeutic area |
|---|---|---|---|---|
| FDBD00498 | Dexmedetomidine |
|
Hypnotics and Sedatives; Analgesics, Non-Narcotic; Adrenergic alpha-2 Receptor Agonists; Nervous System; Psycholeptics; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP1A2 Inducers; CYP2D6 Inducers; CYP2D6 Inducers (strong); CYP2E1 Inhibitors; CYP2E1 Inducers; CYP2E1 Inducers (strong); Alpha2 Agonists; | For sedation of initially intubated and mechanically ventilated patients during treatment in an intensive care setting, also used in pain relief; anxiety reduction and analgesia. |
| FDBD00647 | Mefenamic acid |
|
Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase Inhibitors; Musculo-Skeletal System; Antiinflammatory and Antirheumatic Products, Non-Steroids; Antiinflammatory and Antirheumatic Products; Fenamates; Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP2C8 Inhibitors; Cytochrome P-450 CYP2C9 Inducers; Cytochrome P-450 CYP2C8 Inducers; | For the treatment of rheumatoid arthritis, osteoarthritis, dysmenorrhea, and mild to moderate pain, inflammation, and fever. |
| FDBD01019 | Orphenadrine |
|
Antiparkinson Agents; Muscarinic Antagonists; Parasympatholytics; Muscle Relaxants, Central; Antidyskinetics; Muscle Relaxants, Skeletal; Musculo-Skeletal System; Nervous System; Muscle Relaxants, Centrally Acting Agents; Muscle Relaxants; Anti-Parkinson Drugs; Anticholinergics; Ethers Chemically Close to Antihistamines; Cytochrome P-450 CYP2B6 Inducers; Cytochrome P-450 CYP2B6 Inhibitors; CYP2B6 Inhibitors (strong); CYP2E1 Inhibitors; CYP2E1 Inducers; CYP2E1 Inducers (strong); CYP3A4 Inhibitors; | Indicated for the treatment of Parkinson's disease. |
| FDBD01387 | Eltrombopag |
|
Thrombopoietic Agents; Blood and Blood Forming Organs; Antihemorrhagics; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP1A2 Inducers; Cytochrome P-450 CYP2C8 Inhibitors; Cytochrome P-450 CYP2C8 Inducers; | Thrombopoietin receptor agonists are pharmaceutical agents that stimulate platelet production in the bone marrow. In this, they differ from the previously discussed agents that act by attempting to curtail platelet destruction. |
| FDBD01568 | Canagliflozin |
|
Hypoglycemic Agents; Drugs Used in Diabetes; Alimentary Tract and Metabolism; Blood Glucose Lowering Drugs, Excl. Insulins; CYP3A4 Inhibitors; | Canagliflozin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Use in type 1 diabetes mellitus patients or in treatment of diabetic ketoacidosis is not recommended. |
| FDBD01912 | xylylcarb |
|
Insecticide | Insecticide |
| FDBD02310 | thiofluoximate |
|
Insecticide | Insecticide |
| FDBD02312 | pyrimidifen |
|
Insecticide | Insecticide |
| FDBD02424 | xylachlor |
|
Herbicide | Herbicide |
| FDBD02856 | cinmethylin |
|
Herbicide | Herbicide |
10 ,
2
| FRAGNAME | PDBID | SIMILIRITY | XSCORE | SMILE | HAC |
|---|---|---|---|---|---|
| 188l_ligand_frag_0.mol2 | 188l | 1 | -7.46 | c1(c(cccc1)C)C | 8 |
| 188l_ligand.mol2 | 188l | 1 | -7.46 | c1(c(cccc1)C)C | 9 |
| 1msm_ligand_1_8.mol2 | 1msm | 1 | -7.08 | Cc1ccccc1C | 8 |
| 3gz9_ligand_frag_2.mol2 | 3gz9 | 1 | -7.07 | c1cccc(c1C)C | 8 |
| 3fej_ligand_1_2.mol2 | 3fej | 1 | -7.06 | Cc1c(cccc1)C | 8 |
| 1kzk_ligand_1_8.mol2 | 1kzk | 1 | -7.05 | c1(ccccc1C)C | 8 |
| 2xn3_ligand_frag_2.mol2 | 2xn3 | 1 | -7.00 | c1c(c(ccc1)C)C | 8 |
2616 ,
262
